A novel antiangiogenetic approach for adjuvant therapy of pancreatic carcinoma

Peer Joensson, Birgit Hotz, Mehran Dadras, Heinz Johannes Buhr & Hubert Hotz
Introduction: Surgical therapy remains the only curative option for pancreatic ductal adenocarcinoma. But even after complete resection, almost all patients suffer from local tumor recurrence. Current standard adjuvant therapy with gemcitabine does not impressively affect the recurrence rate. The aim[for full text, please go to the a.m. URL]